Introduction
Deep Genomics is a Toronto-based AI-first TechBio organization founded in 2015 by Brendan Frey that applies deep learning foundation models to decode RNA biology and accelerate therapeutic discovery across ASO, siRNA, and mRNA modalities. Brian O’Callaghan serves as chief executive officer per Deep Genomics’ team page reviewed in July 2026 — a leadership fact Brel verifies directly from the company site rather than third-party databases that may list outdated executives. Frey remains founder and chief innovation officer, continuing as the scientific voice for the company’s foundation model platform.
On May 19, 2025, Deep Genomics announced REPRESS (Regulatory Element PRediction of post-transcriptional Events using Sequence Signals), a foundation model predicting microRNA binding and mRNA degradation directly from RNA sequences — extending the company’s platform into post-transcriptional regulation previously difficult to model at therapeutic design scale.
What the company does
Deep Genomics builds a cohesive multi-model Foundation Model Platform that accelerates target identification and therapeutic design across RNA modalities. REPRESS analyzes patient mutations and therapeutic approaches acting through mRNA stability — a biologically critical layer for maintaining normal protein levels or boosting therapeutic protein expression. Trained on millions of miRNA-mRNA interaction and degradation sites from human and mouse tissues, REPRESS outperformed seven leading methods across seven benchmarks including variant effect prediction and modeling canonical and non-canonical miRNA repression, per Deep Genomics’ May 2025 announcement.
REPRESS complements Deep Genomics’ proprietary models for RNA processing and RNA editing, forming a unified system where models collaborate on comprehensive target identification rather than operating as isolated predictors. Lead scientist Bhargav Kanuparthi stated REPRESS is the first foundation model of its kind for therapeutically relevant mRNA stability mechanisms — incorporated into the platform for ASO, siRNA, and mRNA therapeutic design workflows.
Deep Genomics released REPRESS for non-commercial use via GitHub, per the official release — a distribution choice that lets academic researchers validate model performance independently while commercial therapeutic programs remain internal and partnered.
Who it serves
Deep Genomics serves biopharmaceutical organizations and internal pipeline teams designing RNA-targeted therapeutics where sequence-level prediction of regulatory mechanisms determines candidate viability. Frey framed REPRESS as offering a new lens into a previously obscure layer of gene regulation — relevant to developers who previously relied on low-throughput experimental assays to infer miRNA effects on mRNA stability.
Academic researchers access REPRESS non-commercially through Deep Genomics’ GitHub repository; pharmaceutical partners engage the full Foundation Model Platform for proprietary therapeutic programs spanning multiple RNA modalities.
Company background
Frey founded Deep Genomics in 2015 in Toronto, bringing machine learning and genomics research credentials to a TechBio model combining AI scientists and biology researchers under one organization. The company maintains offices in Toronto and Cambridge, Massachusetts, per its corporate boilerplate. O’Callaghan leads executive operations as CEO while Frey drives innovation strategy as founder and CIO — a division reflecting Deep Genomics’ identity as research-intensive biotech rather than software vendor.
Brel uses 2015 as founding year per Deep Genomics team page; prior CSV data listing 2014 is superseded by official company source reviewed July 2026.
Product and AI capabilities
Deep Genomics’ foundation models learn directly from sequence to predict post-transcriptional regulatory events — miRNA binding sites and mRNA degradation patterns — without requiring intermediate feature engineering that older bioinformatics pipelines needed. Frey stated in the May 2025 release that REPRESS demonstrates innovation when AI and biology are deeply integrated, bringing Deep Genomics closer to designing more precise and effective therapeutics.
Cross-model collaboration within the platform lets RNA processing, editing, and REPRESS stability models inform joint target ranking — a systems approach distinct from single-task variant predictors common in earlier genomic AI tools.
Key developments
2015: Deep Genomics founded in Toronto by Brendan Frey (team page; supersedes CSV 2014 date). May 19, 2025: REPRESS foundation model announced for miRNA binding and mRNA degradation prediction (deepgenomics.com news, official source). 2026: Brian O’Callaghan CEO; Brendan Frey Founder and CIO per team page.
REPRESS GitHub release enables external benchmark replication — a transparency practice Brel notes for readers evaluating foundation model claims in RNA therapeutic design.
Why it matters
Deep Genomics matters because RNA therapeutics — ASO, siRNA, and mRNA — depend on understanding post-transcriptional regulation that DNA-centric genomics platforms under-model. REPRESS is a May 2025 concrete platform expansion with published benchmark superiority claims against seven competing methods, not a preclinical press release without validation data. O’Callaghan’s CEO role signals operational scaling alongside Frey’s continued scientific leadership.
Deep Genomics complements small-molecule AI vendors such as Atomwise (Numerion Labs) within Brel biotechnology coverage — buyers should align platform modality focus with pipeline chemistry before partnership discussions.
Sector context
Deep Genomics belongs in Brel’s AI in healthcare coverage under biotechnology and AI drug discovery, related to rare-disease platform biotechs like Healx but focused on RNA biology foundation models. Readers should monitor Deep Genomics pipeline IND milestones separately from open-source REPRESS academic releases — model availability does not equal therapeutic approval.
RNA therapeutic developers evaluating Deep Genomics should request modality-specific validation — ASO design constraints differ materially from mRNA stability optimization even within one foundation platform.
Sources and references
Deep Genomics REPRESS news release (May 19, 2025) and Team leadership page.
- Deep Genomics — REPRESS foundation model (deepgenomics.com, May 19, 2025)
- Deep Genomics — Team / leadership (deepgenomics.com)
Reviewed July 10, 2026. Brian O’Callaghan is CEO; Brendan Frey is founder and CIO. Founded 2015 per team page.